Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012)
Johnson & Johnson's (JNJ) quarterly Land & Improvements came in at $754.0 million in Q1 2012, up 2.17% year-over-year from $738.0 million in Q1 2011, and up 2.17% quarter-over-quarter from $738.0 million in Q1 2011.
Powered by 
Analysis
Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012) Analysis & Trends
Johnson & Johnson has disclosed Land & Improvements across 2 years of filings, most recently posting $754.0 million for Q1 2012.
- In Q1 2012, Land & Improvements rose 2.17% year-over-year to $754.0 million; the TTM figure through Jan 2012 stood at $754.0 million (up 2.17% YoY), while the FY2012 annual figure was $754.0 million, up 2.17% from the prior year.
- Land & Improvements came in at $754.0 million for Q1 2012 at Johnson & Johnson, up from $738.0 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $754.0 million in Q1 2012 to a low of $738.0 million in Q1 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 157.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |